Pfizer Weighing Options In Medical Technology Group Divestment
This article was originally published in The Gray Sheet
Executive Summary
Schneider's rapid-exchange balloon catheter patent portfolio will be a key draw for firms considering whether to acquire the Pfizer unit, which has annual sales of $330 mil. On Feb. 26, the drug maker announced that it is "exploring strategic options" for divesting its $1.45 bil. medical technology group (MTG), which, in addition to Schneider, includes Howmedica ($880 mil.) and American Medical Systems ($90 mil.).